PPARγ dependence of cyclosporine-isoprenaline renovascular interaction: Roles of nitric oxide synthase and heme oxygenase

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 2, 2011, Pages 173-180

  El Gowelli, Hanan M ^a   Abd Elrahman, Khaled S ^a   Saad, Evan I ^a   El Gowilly, Sahar M ^a   Abdel Galil, Abdel Galil A ^a   El Mas, Mahmoud M ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

cyclosporine; heme oxygenase; isoprenaline; nitric oxide synthase; peroxisome proliferator activated receptor gamma; renal vasodilation

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ARGININE; BETA ADRENERGIC RECEPTOR; CYCLOSPORIN A; HEME OXYGENASE; HEMIN; ISOPRENALINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTOPORPHYRIN ZINC;

ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE; KIDNEY BLOOD VESSEL; KIDNEY PARENCHYMA; KIDNEY PERFUSION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; VASODILATATION;

ANIMALS; CYCLOSPORINE; DRUG INTERACTIONS; ENZYME INHIBITORS; HEME OXYGENASE (DECYCLIZING); ISOPROTERENOL; KIDNEY; MALE; NITRIC OXIDE SYNTHASE; PPAR GAMMA; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA; THIAZOLIDINEDIONES; VASODILATION;

EID: 80051781419     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31821ed803     Document Type: Article

References (46)

1. Calne RY, White DJG, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978;2:1323-1327.
2. Myers BD. Cyclosporine nephrotoxicity. Kidney Int. 1986,30:964-974.
3. Gillum DM, Truong L, Tasby J, et al. Chronic cyclosporine nephrotoxicity. Transplantation. 1988;46:285-292.
4. Merion RM, White DJG, Thiru S, et al. Cyclosporine: Five years' experience in cadaveric renal transplantation. N Engl J Med. 1984;310: 148-154.
5. Mason J. Pharmacology of cyclosporine (Sandimmune). VII. Pathophysiology and toxicology of cyclosporine in humans and animals. Pharmacol Rev. 1990;41:423-434.
6. El-Mas MM, Mohy El-Din MM, El-gowilly SM, et al. Relative roles of endothelial relaxing factors in cyclosporine-induced impairment of cholinergic and b-adrenergic renal vasodilations. Eur J Pharmacol. 2004;487:149-158.
7. Rego A, Vargas R, Suarez KR, et al. Mechanism of cyclosporin potentiation of vasoconstriction of the isolated rat mesenteric arterial bed: Role of extracellular calcium. J Pharmacol Exp Ther. 1990;254: 799-808.
8. Mathieu P, Carrier M, Dupuis J, et al. L-arginine prevents cyclosporin A-induced pulmonary vascular dysfunction. Ann Thorac Surg. 1997;64: 414-420.
9. Rego A, Vargas R, Wroblewska B, et al. Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A. J Pharmacol Exp Ther. 1990;252:165-170.
10. El-Mas MM, Mohy El-Din MM, El-gowilly SM, et al. Regional and endothelial differences in the cyclosporine attenuation of adenosine receptor-mediated vasorelaxations. J Cardiovasc Pharmacol. 2004;43: 562-573.
11. Abbott BD. Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol. 2009;27: 246-257.
12. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int. 2001; 60:14-30.
13. Marx N, Bourcier T, Sukhova GK, et al. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol. 1999;19:546-551.
14. Heppner TJ, Bonev AD, Eckman DM, et al. Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pharmacology. 2005;73:15-22.
15. Wakino S, Hayashi K, Tatematsu S, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res. 2005;28:255-262.
16. UetaM,Wakisaka M, Ago T, et al. PPAR-gamma ligands attenuate mesangial contractile dysfunction in high glucose. Kidney Int. 2004;65:961-971.
17. PereiraMG, Cǎmara NO, Campaholle G, et al. Pioglitazone limits cyclosporine nephrotoxicity in rats. Int Immunopharmacol. 2006;6:1943-1951.
18. Chung BH, Li C, Sun BK, et al. Rosiglitazone protects against cyclosporineinduced pancreatic and renal injury in rats. Am J Transplant. 2005;5: 1856-1867.
19. Chung BH, Lim SW, Ahn K.O, et al. Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and nondiabetic renal diseases. Nephrology (Carlton). 2005;10:S40-S43.
20. Nasr MA, El-gowilly SM, El-Mas MM. Comparable renovascular protective effects of moxonidine and Simvastatin in rats exposed to cigarette smoke. Vascul Pharmacol. 2010,53;53-60.
21. Majithiya JB, Paramar AN, Balaraman R. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res. 2005;66:150-161.
22. Nizamutdinova IT, Kim YM, Kim HJ, et al. Carbon monoxide (from CORM-2) inhibits high glucose-induced ICAM-1 expression via AMPactivated protein kinase and PPAR-gamma activations in endothelial cells. Atherosclerosis. 2009;207:405-411.
23. El-Mas MM, El-gowilly SM, Gohar EY, et al. Pharmacological characterization of cellular mechanisms of the renal vasodilatory effect of nicotine in rats. Eur J Pharmacol. 2008;588:294-300.
24. El-gowilly SM, Ghazal AM, Gohar EY, et al. Exacerbation by nicotine of the cyclosporine A-induced impairment of b-adrenoceptor-mediated renal vasodilation in rats. Clin Exp Pharmacol Physiol. 2008;35:1164-1171.
25. Ushiyama M, Morita T, Katayama S. Carbon monoxide regulates blood pressure cooperatively with nitric oxide in hypertensive rats. Heart Vessels. 2002;16:189-195.
26. Camacho IE, Serneels L, Spittaels K, et al. Peroxisome- proliferatoractivated receptor gamma induces a clearance mechanism for the amyloidbeta peptide. J Neurosci. 2005;24:10908-10917.
27. Ndisang JF, Zhao W, Wang R. Selective regulation of blood pressure by hemeoxygenase-1 in hypertension. Hypertension. 2002;40:315-321.
28. Lindgren EM, Nielsen R, Petrovic N, et al. Noradrenaline represses PPAR (peroxisome-proliferator-activated receptor) gamma2 gene expression in brown adipocytes: Intracellular signaling and effects on PPARgamma2 and PPARgamma1 protein levels. Biochem J. 2004;382:597-606.
29. Hughes TA, Stentz F, Gettys T, et al. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects. Metabolism. 2006;55:26-34.
30. Chang L, Villacorta L, Zhang J, et al. Vascular smooth muscle cellselective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation. 2009;119:2161-2169.
31. Ueki S, Usami A, Oyamada H, et al. Procaterol upregulates peroxisome proliferator-activated receptor-gamma expression in human eosinophils. Int Arch Allergy Immunol. 2006;140(suppl 1):35-41.
32. van der Zypp A, Kang KB, Majewski H. Age-related involvement of the endothelium in beta-adrenoceptor-mediated relaxation of rat aorta. Eur J Pharmacol. 2000;397:129-138.
33. MustafaMR, Johns EJ. The role of haem oxygenase in renal vascular reactivity in normotensive and hypertensive rats. J Hypertens. 2001;19:1105-1111.
34. Rezzani R, Rodella L, Bianchi R, et al. Protective effects of hemeoxygenase expression in cyclosporine A-induced injury. Curr Neurovasc Res. 2005;2:157-161.
35. Hoetzel A, Dolinay T, Vallbracht S, et al. Carbon monoxide protects against ventilator-induced lung injury via PPAR-gamma and inhibition of Egr-1. Am J Respir Crit Care Med. 2008;177:1223-1232.
36. Kurtz A, Götz KH, Hamann M, et al. Mode of nitric oxide action on the renal vasculature. Acta Physiol Scand. 2000;168:41-45.
37. Han J, Kim N, Kim E, et al. Modulation of ATP-sensitive potassium channels by cGMP-dependent protein kinase in rabbit ventricular myocytes. J Biol Chem. 2001;276:22140-22147.
38. Han DH, Bai GY, Yang TK, et al. The effect of papaverine on ion channels in rat basilar smooth muscle cells. Neurol Res. 2007;29:544-550.
39. Quayle JM, Standen NB. K ATP channels in vascular smooth muscle. Cardiovasc Pharmacol. 1994;28:797-804.
40. Liu G, Shi J, Yang L, et al. Assembly of a Ca2+-dependent BK channel signaling complex by binding to beta2 adrenergic receptor. EMBO J. 2004;23:2196-2205.
41. Ahn KO, Lim SW, Yang HJ, et al. Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat. Yonsei Med J. 2007;48:308-316.
42. Rampino T, Ranghino A, Guidetti C, et al. Activation of PPARgamma enhances in vitro the immunosuppressive effect of cyclosporine on T lymphocytes. Transpl Immunol. 2007;18:32-36.
43. Tanaka Y, Hasegawa T, Chen Z, et al. Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation. J Thorac Cardiovasc Surg. 2009;138:744-751.
44. Chander V, Chopra K. Effect of molsidomine and L-arginine in cyclosporine nephrotoxicity: Role of nitric oxide. Toxicology. 2005;207: 463-474.
45. Foresti R, Bani-Hani MG, Motterlini R. Use of carbon monoxide as a therapeutic agent: Promises and challenges. Intensive Care Med. 2008; 34:649-658.
46. Einollahi B, Taheri S, Lessan-Pezeshki M, et al. Approach to a target value for 2-hours post dose cyclosporine (C2) during the first week post renal transplantation. Ann Transplant. 2009;14:18-22.